2026 Biomedical Pitch Competition
Day 2 Forum and Networking
70 個名額
現場參會請於 5/19 前完成報名
主題： Bridging the Gap: From Lab to Market in a Global Ecosystem
日期： 2026 年 5 月 24 日（星期日）
時間： 上午 9:00 – 下午 12:30（半日研討會）
地點：
Fish & Richardson P.C 會議廳（17 樓）
1 Marina Park Drive, Boston, MA 02210
主辦方：
Boston Capital Investment Club (BCIC)
Hong Kong Science and Technology Parks Corporation (HKSP)
活動概述
繼 2026 Biomedical Pitch Competition 之後，本次研討會匯聚国際專家，共同打通商業化的"最後一公里"，並促進戰略合作與人脈對接。
議程
-
09:00 AM – 09:10 AM：開幕致辭
-
Jonathan Yi, President of BCIC
-
09:10 AM – 09:30 AM：Keynote I
-
演講嘉賓： Weng-li Yoon, Associate Director, HKSTP
-
主題： Hong Kong as Asia's Emerging Biotech Hub.
-
09:30 AM – 09:40 AM：Keynote II — 場地贊助方致辭 Fish & Richardson P.C.
-
演講嘉賓： Peng Lin, Partner, Fish & Richardson P.C.
-
09:40 AM – 11:00 AM：Panel Discussion — The Multi-Dimensional Launchpad
-
深入探討 VC、CRO、Regulatory 與 Accelerator 多維視角。
-
嘉賓：
-
Weng-li Yoon, Associate Director, HKSTP
-
Peng Lin, Partner, Fish & Richardson P.C
-
Kate Zhang, Venture Partner at Tailwinds (NLVC)
-
Baolin (John) Wu, Executive Director of Technical Business Development
-
Han Zhang, Managing Director of BCIC
-
11:00 AM – 12:30 PM：Hybrid Networking & Close
報名信息
- 現場參會： 名額有限（70 位）
- 費用： $20
https://bcic.ticketspice.com/2026-biomedical-pitch-competition-forum-and-networking-part
Keynote 演講嘉賓與 Panelist 簡介
Wengli Yoon, Ph.D.
Associate Director (Therapeutics), Hong Kong Science and Technology Parks Corporation (HKSP)
Weng Li 是一位資深生物科技 R&D 領導者，在初創企業及跨国公司環境中擁有 20 餘年国際經驗，常駐英国與香港。
在 HKSTP 的現職中，Weng Li 與團隊負責管理 HKSTP 內所有治療領域企業的入駐與支持，涵蓋 small molecules、biologics、cell and gene therapy、傳統中醫藥及營養健康等模式。她同時領導 Clinical Translational Catalyst 項目，為 HKSTP 入駐企業的 IND-enabling 研究及臨床試驗提供資金支持。此外，她還在與香港大學和香港中文大學的聯合管理委員會任職，負責籌建 cell and gene therapy 的 PIC/S GMP 中試生产設施。
Peng Lin, Ph.D.
Principal of Fish & Richardson P.C.
Peng 的客戶涵蓋大型上市生物制藥公司及全球范圍內的初創企業。他參與客戶企業各成長階段的工作，致力於深入理解客戶技術，制定最優 IP 策略以最大化客戶發明的商業價值。
Peng 以榮譽成績畢業於 Harvard Law School。法學院前，他在 Washington University in St. Louis 取得人類遺傳學與統計遺傳學博士學位。Peng 在人類遺傳、分子生物學、生物物理與生物信息學方向積累了深厚的研究與訓練經驗。他為客戶提供廣泛技術領域的專利咨詢，包括 antibody therapeutics、transgenic animals、CAR-T 與 TCR-T 免疫療法、microarray 技術、診斷方法、納米顆粒技術、疫苗、small molecules、醫療器械、AI 在制藥行業的應用等。
Peng 長期積極參與華人創業者社區。他自 2016 年起担任 Chinese Antibody Society 志愿者，並在 2024–2026 任期出任主席。Chinese Antibody Society 是一家致力於搭建抗体藥物發現、開發、生产與商業化全球協作平台的非營利組織。
Peng 同時是 Kauffman Fellow（生物創業方向）。
Kate Zhang, Ph.D.
Venture Partner at Tailwinds (NLVC)
Dr. X. Kate Zhang 是一位戰略型科學家與企業家，在生物制藥行業擁有超過 30 年經驗。她目前担任 Tailwinds (NLVC) 的 Venture Partner，憑借在藥物開發方面的深厚背景，為新興生物科技初創公司發掘投資機會並主導深入的科學尽調。Dr. Zhang 此前曾任 Hopewell Therapeutics 的 Chief Scientific Officer 及 Interim CEO，主導了 2,500 萬美元种子輪融資，並為其 tissue-targeting lipid nanoparticle (ttLNP) 平台搭建起完整的 R&D 体系。她的職業經歷還包括在 Editas Medicine 担任 VP of Biological Development，主導多項里程碑式 CRISPR-based IND 申報；並在 Sanofi 和 Genzyme 担任高級管理職位，參與了十款生物藥的成功上市。Dr. Zhang 擁有超過 45 篇同行評議論文及多項專利，博士學位獲自 Queen's University，並在 NIH 完成博士後訓練。
Han Zhang (Moderator), Ph.D.
Managing Director, Boston Capital Investment Club (BCIC)
Han Zhang 博士現任 BCIC 總經理，負責在生命科學生態系統中連接 biotech 創始人、投資人與戰略合作伙伴。他具備跨業務發展、競爭情報、生物醫學信息學與轉化科學的復合背景。早年他曾參與 Annoroad Gene Technology 創始團隊，並陪伴公司走過 IPO 的成長歷程。他亦曾任職於 Bristol Myers Squibb 與 SAS，積累了在生物制藥、數據科學與分析領域的丰富經驗。憑借生物醫學信息學訓練與對商業化策略的濃厚興趣，Han 致力於在科學創新與市場洞察、合作策略及投資對話之間架起橋梁。
Baolin (John) Wu, Ph.D.
Executive Director of Technical Business Development
Dr. Baolin (John) Wu 是醫藥 CRDMO 行業的資深領導者，在 BD、客戶管理、工藝開發與項目管理方面擁有 12 年以上經驗。他擅長 small-molecule 開發與商業化生产，並在 ICH Q7 合規的 cGMP 運營方面有深厚積累。Dr. Wu 與全球生物制藥及生物科技伙伴在復雜的開發與生产項目上緊密合作，並曾管理年收入超過 3,000 萬美元的戰略客戶組合。在轉任商業領導職位之前，Dr. Wu 參與了 40 餘項臨床與商業化生产項目以及 50 餘項中美兩地的開發與商業化項目。他的技術背景包括工藝放大、技術轉移、連續流化學與酶催化轉化。Dr. Wu 在 Wayne State University 獲有機化學博士學位，並在工藝化學與相关領域合著了 17 篇科學論文。
Co-organizers and Sponsors
Name
Description
Boston Capital Investment Club (BCIC)
The Boston Capital Investment Club (BCIC) is a Massachusetts-registered non-profit organization serving nearly 10,000 professionals in finance, venture capital, and various technology industries. Beyond being a Boston-centered platform, the BCIC has grown to facilitate nationwide and international knowledge exchange across healthcare, finance, and related fields. Since 2022, the organization has hosted annual biomedical pitch competitions, empowering startups to secure over $300 million in collective funding.
Hong Kong Science and Technology Parks Corporation (HKSTP)
With a 20-year history of transforming lives through innovation, technology and entrepreneurship, Hong Kong Science and Technology Parks Corporation (HKSTP) has been propelling success for the most creative minds and innovators around the globe, accelerating ambitions and delivering positive impact from Hong Kong to the Greater Bay Area and the world. As an advocate for the innovative spirit, we strive to cultivate a diverse talent pool, connect research to innofacturing through "new industrialisation", and create a well-established I&T ecosystem that bridges innovators with high-potential partners and investors for ideas to grow and thrive.https://www.hkstp.org/
Fish & Richardson P.C.
As the leading IP law firm, we help innovators change the world through our unmatched litigation, prosecution, and post-grant experience across venues and prosecution needs. We touch more PTAB cases, IP appeals, and utility patents than anyone else, and no national firm handles more district court patent cases. Many of our 450+ attorneys and technology specialists are also scientists who are as comfortable in a lab or cleanroom as a courtroom or patent office. We're ready to hit the ground running to support your innovations, while distilling our vast technical and legal knowledge to resonate with business leaders or juries. You can be confident in every Fish lawyer in your corner because we intentionally build talent from the ground up and share knowledge generously and eagerly across the firm, leading to faster, fuller insights for you. Visionaries across eras have trusted us to protect their IP — from Alexander Graham Bell to today's largest phone makers — and we're ready to help build your IP strategy today with tomorrow in mind. Let's change the world together.
Shanghai InnoStar
Shanghai InnoStar Bio-tech Co., Ltd. (InnoStar), was established in 2010. As a leading contract research organization, we adhere to the core values of "Science orientated, Quality first, Integrity & dedication, Win-win cooperation", and strive for innovative and reputational services with high quality and excellence. Over the past decade, InnoStar has successfully passed GLP inspections by various national and international authorities, including US FDA, and received the GLP certification from the National Medical Products Administration (NMPA), OECD GLP certification GLPmonitoring authority, AAALAC certification, and CAP certification from the College of American Pathologists (CAP), etc. Our business scope covers screening and discovery services, nonclinical pharmacodynamics, nonclinical pharmacokinetics, nonclinical safety evaluation, clinical sample bioanalysis, biomarkers and translational research. InnoStar was listed on the STAR Market of Shanghai Stock Exchange on September 3, 2024 (Stock code: 688710).
Porton Pharma Solutions Ltd
Founded in 2005, Porton Pharma Solutions Ltd. is an internationally recognized pharmaceutical contract development and manufacturing organization (CDMO) in enabling our global clients to optimize drug development and manufacturing. We provide customer development and manufacturing services for Small Molecules, Tides, Biologics and Conjugates (ADCs, AOCs, PDCs, RDCs, etc.), and Advanced Therapy Medicinal Products from pre-clinical to commercialization stages.
PanaCRO
PanaCRO is a full-service clinical CRO founded in 2004, helping global biotech and biopharma companies accelerate clinical development in China. With 500+ employees, coverage across 20+ provinces, collaboration with 800+ research sites, and experience supporting 200+ customers and 200+ clinical trials, PanaCRO provides end-to-end solutions from pre-IND/IND strategy and regulatory support to investigator-initiated trials (IITs), Phase I–III studies, NDA/BLA registration, and post-market real-world studies. With strong expertise in oncology, autoimmune diseases, infectious diseases, metabolic disorders, CNS, ophthalmology, and vaccines, PanaCRO combines deep local regulatory knowledge with international ICH-GCP standards to deliver efficient, high-quality clinical execution. As a trusted partner for innovative drug development, PanaCRO helps sponsors navigate China's clinical and regulatory landscape with speed, quality, and confidence
Simcere Pharmaceutical Group
Simcere Pharmaceutical Group is an innovation and R&D-driven pharmaceutical company with capabilities in R&D, production and professional marketing. It primarily focuses on the therapeutic areas of oncology, nervous system, autoimmune and antiinfection, with proactive forward-looking layout of disease areas that have significant clinical needs in the future, aiming to achieve the corporate mission of "providing today's patients with medicines of the future". Driven by its in-house R&D efforts and synergistic innovation, Simcere has established strategic cooperation partnerships with many MNC, innovative companies, research institutes and clinical centers. In addition, Simcere has established several R&D innovation centers around the world. One of the innovation centers is Boston Innovation Center, located in Cambridge.
Fenwick
Fenwick is a top law firm serving technology and life sciences clients. With 500+ attorneys, we are nationally recognized for strengths in complex transactions, IP protection, M&A, "bet‑the‑company" litigation, and domestic and international tax. Since the 1980s, we've advised on international outsourcing, IP enforcement, foreign investment, and cross‑border tax matters. Our lawyers combine deep technical knowledge with a commitment to efficient, high‑quality service in a collaborative environment. Fenwick's landmark work includes incorporating Apple; pioneering the first shrink‑wrap license; negotiating an early software license with Bill Gates; taking Oracle, eBay, and 180+ others public; defending key biotech patents; and handling many of the industry's largest and most significant mergers and acquisitions.
